Combination treatment for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two treatments for advanced liver cancer that cannot be removed by surgery: drug-coated bead chemoembolization (DEB-TACE) and a chemotherapy infusion into the liver artery (SALOX-HAIC). The goal is to see if this combination can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer that cannot be surgically removed and has at least one tumor that can be measured on a scan.
- Your cancer is at a specific stage (CNLC Ib-IIIa or BCLC A-C).
- You are between 18 and 80 years old.
- You are in good enough health to perform daily activities (ECOG score 0 or 1).
- Your liver function is good enough (Child-Pugh class A or B) and your blood counts and other lab tests are within certain limits.
- You have not had certain previous treatments for liver cancer, such as TACE, radiation, targeted pills, or immunotherapy.
- You do not have certain conditions like large tumor burden, blood clotting problems, recent bleeding, or HIV infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests a combination of three treatments—two immunotherapy/anti-cancer drugs (bevacizumab and atezolizumab) plus a catheter-based liver treatment (TACE-HAIC)—for people with unresectable hepatocellular carcinoma (liver cancer that cannot be surgically removed). The goal is to slow or shrink the cancer.
This trial tests a combination of treatments for people with liver cancer that can be surgically removed. The goal is to see if the combination helps shrink tumors and improve outcomes before surgery.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.